Posted inSectors

Battle against COVID-19: Ajanta Pharma commits Rs. 6 cr

Rs 2 cr. has been directly contributed to Prime Minister CARES Fund and the rest Rs. 4 cr. is being spent other activities

Battle against COVID-19: Ajanta Pharma commits Rs. 6 cr

Ajanta Pharma commits Rs. 6 crore to fight COVID-19 pandemic. From that Rs 2 cr. has been directly contributed to Prime Minister CARES Fund and the rest Rs. 4 cr. is being spent on the below activities:

Providing Ventilators, Thermal Thermometers, sanitizers and protective gears such as Latex Gloves, Gamex Gloves, N-95 Masks, PPE Kits, etc. to Government of Maharashtra, Brihanmumbai Municipal Corporation and other agencies.
Distribution of food grains to migrant labourers and daily wage earners across different locations.
Providing medicines free of cost to various authorities and organization.

Ajanta Pharma is firmly standing with Govt. of India and State Governments in its efforts to overcome this pandemic. The company has mentioned its statement that it recognises and appreciates their prompt and tireless efforts to contain the spread of COVID-19, while ensuring the availability of the essentials to the nation. It further says that it is also grateful from the core of our heart to the entire medical fraternity for their selfless efforts to protect the humanity.

Ajanta Pharma continues to strive hard to maintain un-interrupted supply of life-saving drugs in India and across the world with the help of Ajantaites, who are committed to play their roles during this global crisis.

Talking about the contribution Yogesh Agrawal, Managing Director, Ajanta Pharma said: “Ajanta’s mission to serve global healthcare needs through empathy, innovation and technology has come to the fore with the Company standing with the government and patients to overcome the humanitarian crisis triggered by the global spread of COVID-19. We salute the doctors, medical staffs and government authorities working selflessly for the cause and promise to tirelessly work towards ensuring availability of essential medicines.”